Varian Medical Systems receives FDA clearance for its Pivitol Care Solution for prone breast treatment and to update its Clinac and Trilogy targeted radiotherapy devices. Varian Medical Systems Inc. (NYSE:VAR) won FDA clearance to update the control software for its Clinac and Trilogy targeted radiotherapy devices and its new Pivitol Care Solution for prone breast treatment. The software approval from the federal watchdog agency allows the Palo Alto, Calif.-based company's devices to deliver higher doses two times faster than previously possible at 2400 monitor units per minute.
